It hasn't been the best quarter for DexCom, Inc. (NASDAQ:DXCM) shareholders, since the share price has fallen 18% in that time. But that scarcely detracts from the really solid long term returns ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

SAN DIEGO, May 01, 2025--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA ...

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 ...

Several Dexcom analysts raised their share-price targets for the diabetes-treatment company after its fourth-quarter earnings beat Wall Street’s estimates. Shares of the San Diego medical-device ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...

The medical device maker has already made impressive gains. A planned stock split may make shares even more attractive to investors. DexCom's robust business performance is reflected in its surging ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...